Business Context and Reporting Period
Company: InMed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 21, 2023
Reporting Period: Event-based disclosure regarding a scheduled investor presentation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate event rather than financial performance data.
Material Changes
No material changes to financial position or operations were reported in this filing. The document serves to disclose a scheduled regulatory communication event.
Guidance, Outlook, and Management Commentary
- Event Announcement: Jerry Griffin, VP of Sales and Marketing for the subsidiary BayMedica LLC, is scheduled to participate in the Water Tower Research Fireside Chat Series.
- Event Details: The presentation is set for July 25, 2023, at 2:00 pm ET.
- Business Focus: BayMedica is described as a leading supplier of bioidentical rare cannabinoids to the Health and Wellness market.
- Regulatory Status: The information is furnished under Item 7.01 (Regulation FD Disclosure) and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the date and time of the Water Tower Research Fireside Chat (July 25, 2023, 2:00 pm ET).
- Confirm the role of Jerry Griffin as VP of Sales and Marketing for BayMedica LLC.
- Review the attached news release (Exhibit 99.1) for specific details on the presentation content.
- Note that this filing does not contain updated financial statements or forward-looking financial guidance.